Mouse Monoclonal Antibody to SHH

Mouse IgG1

MW: 49.6kDa
Enterez GeneID: 6469
General Information: This gene encodes a protein that is instrumental in patterning the early embryo. It has been implicated as the key inductive signal in patterning of the ventral neural tube, the anterior-posterior limb axis, and the ventral somites. Of three human proteins showing sequence and functional similarity to the sonic hedgehog protein of Drosophila, this protein is the most similar. The protein is made as a precursor that is autocatalytically cleaved; the N-terminal portion is soluble and contains the signalling activity while the C-terminal portion is involved in precursor processing. More importantly, the C-terminal product covalently attaches a cholesterol moiety to the N-terminal product, restricting the N-terminal product to the cell surface and preventing it from freely diffusing throughout the developing embryo. Defects in this protein or in its signalling pathway are a cause of holoprosencephaly (HPE), a disorder in which the developing forebrain fails to correctly separate into right and left hemispheres. HPE is manifested by facial deformities. It is also thought that mutations in this gene or in its signalling pathway may be responsible for VACTERL syndrome, which is characterized by vertebral defects, anal atresia, tracheoesophageal fistula with esophageal atresia, radial and renal dysplasia, cardiac anomalies, and limb abnormalities. Additionally, mutations in a long range enhancer located approximately 1 megabase upstream of this gene disrupt limb patterning and can result in preaxial polydactyly.
Immunogen: Purified recombinant fragment of human SHH (AA: 26-161) expressed in E. Coli. ; ;
Size and Concentration: 100ug/1mg/ml
Supplied As: Lyophilized Powder from 100ul of Purified antibody in PBS with 0.05% sodium azide
Reconstitution and Storage: Reconstituted with 100ul sterile DI H2O, at stored at 4C or -20C for short or long term storage.
Applications: ELISA: 1 to 10000; WB: 1 to 500 - 1 to 2000; IHC: 1 to 200 - 1 to 1000; FCM: 1 to 200 - 1 to 400
References: 1. Neuro Oncol. 2011 Jun; 13(6):622-34. ; 2. Breast Cancer Res. 2009; 11(4):R60. ;